|
Symbol |
Object Name |
Qualifiers |
Evidence |
Notes |
Source |
PubMed Reference(s) |
RGD Reference(s) |
Position |
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA thiacloprid results in increased expression of ABCC3 mRNA |
CTD |
PMID:32745781 PMID:33426623 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP ISO |
thiacloprid results in decreased activity of ACHE protein |
CTD |
PMID:21251949 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Alb |
albumin |
multiple interactions decreases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in decreased expression of ALB protein] |
CTD |
PMID:34564187 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO EXP |
thiacloprid results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression |
ISO |
thiacloprid results in decreased expression of ATG5 mRNA; thiacloprid results in decreased expression of ATG5 protein |
CTD |
PMID:37468076 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Cat |
catalase |
decreases activity decreases expression multiple interactions |
EXP |
thiacloprid results in decreased activity of CAT protein thiacloprid results in decreased expression of CAT mRNA astaxanthine inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of CAT mRNA] |
CTD |
PMID:28692354 PMID:34564187 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CES2 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein |
CTD |
PMID:32201337 |
|
NCBI chr19:49,884,164...49,898,764
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
thiacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; thiacloprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein] |
CTD |
PMID:16981889 PMID:25459289 |
|
NCBI chr 2:177,479,091...177,487,306
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
thiacloprid results in decreased expression of CREM mRNA; thiacloprid results in decreased expression of CREM protein |
CTD |
PMID:37468076 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
thiacloprid results in increased expression of CYBB mRNA |
CTD |
PMID:32201337 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
thiacloprid results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:37468076 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions affects expression |
ISO |
thiacloprid results in increased activity of CYP19A1 protein thiacloprid results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA] |
CTD |
PMID:26464060 PMID:28750898 PMID:29701941 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
thiacloprid results in increased expression of CYP1A1 mRNA; thiacloprid results in increased expression of CYP1A1 protein |
CTD |
PMID:21784029 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP1A2 mRNA; thiacloprid results in increased expression of CYP1A2 protein [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:21784029 PMID:32201337 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of CYP2B2 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:90,722,243...90,736,272
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA thiacloprid results in increased expression of CYP2B6 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:32201337 PMID:32736067 PMID:32745781 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:246,286,341...246,348,607
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression decreases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP2C19 mRNA thiacloprid results in decreased expression of CYP2C19 protein [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA |
CTD |
PMID:32194361 PMID:32201337 PMID:32745781 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
thiacloprid results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A4 mRNA; thiacloprid results in increased expression of CYP3A4 protein [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA thiacloprid results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A5 mRNA [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
thiacloprid results in decreased expression of CYP7A1 protein [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA thiacloprid results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 PMID:33426623 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddx4 |
DEAD-box helicase 4 |
decreases expression |
ISO |
thiacloprid results in decreased expression of DDX4 mRNA; thiacloprid results in decreased expression of DDX4 protein |
CTD |
PMID:37468076 |
|
NCBI chr 2:45,961,174...46,016,097
Ensembl chr 2:44,227,946...44,282,723
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Eln |
elastin |
multiple interactions decreases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA thiacloprid results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:27,604,983...27,648,413
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein |
CTD |
PMID:32736067 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of GPT protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of GPT protein]; Polysaccharides inhibits the reaction [thiacloprid results in increased expression of GPT protein] |
CTD |
PMID:31328355 PMID:34564187 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of GPX1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in increased expression of HMGB1 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL10 protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL10 protein] |
CTD |
PMID:34564187 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL1B protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL1B protein] |
CTD |
PMID:34564187 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
thiacloprid results in increased expression of IL6 protein |
CTD |
PMID:34564187 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of INS1 protein |
CTD |
PMID:32745781 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ky |
kyphoscoliosis peptidase |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of KY mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:111,965,862...112,005,206
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of MEGF11 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:73,787,568...74,113,228
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
thiacloprid results in decreased expression of MKI67 mRNA; thiacloprid results in decreased expression of MKI67 protein |
CTD |
PMID:37468076 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mme |
membrane metallo-endopeptidase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of MME mRNA [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of NOS2 mRNA astaxanthine inhibits the reaction [thiacloprid results in increased expression of NOS2 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram] |
CTD |
PMID:29950287 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein |
CTD |
PMID:32736067 |
|
NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
thiacloprid results in increased expression of POR mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr X:72,791,096...72,914,299
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases activity |
ISO |
thiacloprid metabolite results in increased activity of SLC22A1 protein; thiacloprid results in increased activity of SLC22A1 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A2 protein; thiacloprid results in decreased activity of SLC22A2 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A8 protein; thiacloprid results in decreased activity of SLC22A8 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of SLC6A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:149,004,447...149,037,840
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of SOD1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
thiacloprid results in decreased expression of STAR mRNA |
CTD |
PMID:37468076 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr14:20,771,917...20,784,665
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sycp3 |
synaptonemal complex protein 3 |
decreases expression |
ISO |
thiacloprid results in decreased expression of SYCP3 mRNA; thiacloprid results in decreased expression of SYCP3 protein |
CTD |
PMID:37468076 |
|
NCBI chr 7:24,761,476...24,775,933
Ensembl chr 7:22,874,055...22,888,511
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA] |
CTD |
PMID:32745781 |
|
NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:151,723,086...151,728,075
|
|